Clinical trials located in

Łódź

Łódź city is located in Poland. Currently, 20 clinical trials are being conducted in this city.

Łódź, Poland’s third-largest city, boasts a unique blend of industrial heritage and vibrant cultural life. Established in the 14th century, it flourished as a textile manufacturing hub in the 19th century, earning the nickname “Polish Manchester.” The city’s rich history is reflected in its eclectic architecture, from grandiose factories and workers’ housing to the opulent residences of industrial magnates along Piotrkowska Street, one of Europe’s longest commercial thoroughfares. Łódź is also renowned for its contributions to cinema, home to the prestigious National Film School, which has nurtured many acclaimed filmmakers.

  • 2019/ABM/01/00024

    Rituximab treatment for children with idiopathic nephrotic syndrome

    This clinical trial focuses on idiopathic nephrotic syndrome (INS), a kidney disorder causing excessive protein loss in the urine, leading to swelling and other complications. The study aims to evaluate the safety and effectiveness of rituximab for children aged 24 months to 16 years with steroid-dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS).

    Participants will be randomly assigned to receive either rituximab or a placebo during a double-blind phase lasting up to 365 days. Following this period, all participants will receive rituximab in an open-label extension phase. The study will monitor the time to the first relapse, assess disease progression, and observe any adverse effects. Regular health assessments, including physical exams, blood tests, and monitoring of disease progression, will be conducted throughout the trial to ensure the safety and well-being of the participants. The goal is to determine if rituximab can extend the period of remission and reduce the frequency of relapses in children with INS.

    • rituximab
    • placebo
  • Baricitinib study in children with juvenile idiopathic arthritis

    This clinical trial is designed to test whether Baricitinib is safe and effective in the treatment of systemic juvenile idiopathic arthritis in children aged 1 to 18 years. Participants will be assigned to one of two groups. In the first group, some participants will receive Baricitinib and others Tocilizumab as the reference drug. In the second group, all participants will receive Baricitinib.

    The primary objective of the study is to evaluate the percentage of participants who experience at least a 30% improvement in disease symptoms after 12 weeks of treatment according to the modified American College of Rheumatology Pediatric Response Criteria (PediACR30). Baricitinib is administered orally and Tocilizumab is administered by subcutaneous injection.

    • Tocilizumab
    • baricitinib
  • Study of the effectiveness of CPL409116 in the treatment of rheumatoid arthritis

    A clinical trial is being presented that focuses on evaluating the efficacy and safety of a new drug called CPL409116 in individuals with active rheumatoid arthritis (RA) who have not achieved improvement with methotrexate alone. The study is designed to last for 12 weeks and aims to enroll approximately 100 participants, who will be divided into four groups. Each group will receive different doses of CPL409116 or a placebo, in addition to their continued methotrexate treatment.

    CPL409116 is a promising drug that works by targeting specific pathways in the body known to contribute to inflammation and RA symptoms. By inhibiting these pathways, CPL409116 could potentially reduce disease activity and improve symptoms. The main objective of this study is to determine how well CPL409116 can decrease disease activity compared to a placebo, which will be measured using the DAS28(CRP) score. This score takes into account the number of swollen or tender joints, the level of a specific protein in the blood that indicates inflammation, and how the patient assesses their disease activity.

    Participants in this study will be randomly assigned to one of the treatment groups and will take the study drug or placebo twice daily for 85 consecutive days. It is important for participants to have been on a stable dose of methotrexate for at least 12 weeks prior to joining the study, with no dosage changes for at least 8 weeks before the study begins.

    This study aims not only to evaluate the efficacy of CPL409116 but also its safety, ensuring that it is well-tolerated by participants. If someone is struggling with active rheumatoid arthritis and has not achieved an adequate response to methotrexate, this study may provide an opportunity to access a potentially new treatment option while contributing to significant research that could benefit other individuals with RA in the future.

    • CPL409116
    • placebo
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    • Zibotentan/Dapagliflozin
    • Dapagliflozin
  • ARTEMIS study: Protecting kidney health in heart surgery patients with Ravulizumab

    The ARTEMIS study aims to find a new way to protect people with chronic kidney disease (CKD) undergoing heart surgery requiring the use of a heart-lung machine, also known as cardiopulmonary bypass (CPB). The main aim of this study is to see if a single dose of a drug called ravulizumab given intravenously can reduce the risk of serious kidney problems after surgery, compared with a placebo. Kidney issues are grouped under serious adverse events, and investigators will monitor them for up to 90 days after surgery. The study is carefully controlled and participants will not know whether they are receiving ravulizumab or a placebo to ensure the results are unbiased. This is an important test for people with chronic kidney disease undergoing heart surgery because it may lead to better outcomes and a lower risk of kidney damage after surgery.

    • placebo
    • Ravulizumab
  • Exploring the safety and effectiveness of somapacitan for growth in children

    The study is focused on evaluating the safety and effectiveness of somapacitan, a new growth hormone treatment. This treatment, given once a week through an injection, aims to assist children who were born small for their gestational age or have been diagnosed with Turner syndrome, Noonan syndrome, or idiopathic short stature. Over a three-year period, the study will monitor for any adverse events or side effects, particularly observing how somapacitan impacts children with these specific  conditions. Participants will receive thorough training from the study team on administering the medication at home. This research is vital for potentially improving treatment and quality of life for children facing growth challenges, emphasizing participant safety and well-being throughout the study process.

    • Somapacitan
  • Sparsentan treatment study for children with Kidney Diseases

    This study involves children with kidney diseases that lead to high levels of protein in the urine. These diseases include Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), Immunoglobulin A Vasculitis (IgAV), and Alport Syndrome (AS). The study will use a drug called Sparsentan, administered as an oral suspension or tablet.

    The goal is to determine if Sparsentan is safe and effective for these children. Participants will receive Sparsentan for 112 weeks, and their progress will be monitored to see if protein levels in their urine decrease and if their overall health improves. The study is open-label, meaning all participants will know they are receiving the drug.

    • Sparsentan
  • Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    • Ibrutinib
    • Ruxolitinib
    • Itacitinib
    • Parsaclisib
  • Testing the effectiveness and safety of povorcitinib in Asthma control

    This study involves an investigation into a medication known as povorcitinib, aimed at assessing its potential benefits for individuals with moderate to severe asthma whose current management is inadequate. The study adopts a ‘double-blind’ approach, ensuring that neither the participant nor the doctor is aware of whether the individual is receiving the actual drug or a placebo – a treatment resembling the drug but lacking any active substance. The focus lies in observing the impact of povorcitinib on lung function over a period of up to 24 weeks, with particular attention to the potential exacerbation of asthma symptoms.

    • povorcitinib
    • ICS-LABA
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    • Capivasertib
    • Docetaxel
  • Study on luspatercept treatment for Myelodysplastic Syndrome

    This study is looking into a medication named Luspatercept and how safe and effective it is for people who have a blood condition known as lower-risk Myelodysplastic Syndrome, or LR-MDS for short. These individuals often need transfusions or have their blood refreshed with new, healthy red blood cells. The drug will be given at its highest approved dose to see what effect it has. This is being done in a controlled and careful way to make sure everything is safe for the participants in the study. People who are taking part in this study have been identified as having a very low to medium risk according to the International Prognostic Scoring System (IPSS-R). This means their disease isnt considered high-risk, which makes them suitable candidates for this research. The study is open-label, meaning everybody knows what is in the drug they are getting.

    • Luspatercept
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    • levoleucovorin
    • leucovorin
    • Fluorouracil
    • Bevacizumab
    • Cetuximab
    • Tucatinib
    • Oxaliplatin
    • Trastuzumab
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    • XXB750
  • Study investigating new medicine for advanced metastatic breast cancer

    A clinical study is investigating the impact and safety of a new medicine named ARV-471 (Vepdegrestrant), contrasting its effects with an already-used drug called fulvestrant (FUL). This research targets individuals suffering from advanced metastatic breast cancer, a disease that often spreads to various parts of the body and is challenging to control. ARV-471 will be given to half of the participants, with the other half receiving fulvestrant. The effects of both will be monitored over time. ARV-471 is consumed by mouth, while FUL is administered through injections.

    • Vepdegrestrant/ARV-471
    • Fulvestrant
  • Evaluating datopotamab deruxtecan & pembrolizumab for advanced lung cancer

    This study compares two treatments for people with a type of lung cancer called ‘non-small cell lung cancer’ that has spread to other parts of the body. It tests whether combining a drug called datopotamab deruxtecan (Dato-DXd) with pembrolizumab works better than using pembrolizumab alone. Aimed at patients with non-small cell lung cancer (NSCLC) who haven’t had previous systemic therapy, it’s especially for those with high PD-L1 tumor expression.

    • Datopotamab deruxtecan
    • Pembrolizumab
  • Testing safety and effects of telisotuzumab and docetaxel in Lung Cancer patients

    This study is for adults who have been treated before for a type of lung cancer called non-small cell lung cancer (NSCLC). The aim is to see if a new drug, called telisotuzumab vedotin, works better and is as safe as a common drug called docetaxel. In this study, cancer activity and any side-effects will be observed closely. The treatment will be given by a drip into a vein.The researchers will randomly decide whether each participant will get telisotuzumab vedotin or docetaxel, with an equal chance of getting either drug. While in the study, each person will have regular hospital or clinic visits to check how they are doing with tests and questionnaires.

    • Telisotuzumab Vedotin
    • Docetaxel
  • Macitentan and selexipag in ongoing pulmonary hypertension care

    This study is for people with a lung disease called pulmonary hypertension (PH) who have taken part in a previous study and are receiving specific treatment. The main goal of the study is to enable these people to continue treatment even after the previous study has ended. The study involves monotherapy with Macitentan or Selexipag and a combination of Macitentan and Tadalafil at fixed doses. All of these drugs are administered orally. The aim of the study is to check how safe the treatment is when used long-term. Will be monitored if any adverse events occur. If this leads to discontinuation of treatment, this will be reported.

    • Selexipag
    • Macitentan/Tadalafil FDC
    • macitentan
  • Comparison of drug combinations in the treatment of advanced lung cancer

    This trial studies a first-line treatment involving Dato-DXd plus pembrolizumab compared to pembrolizumab alone in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The goal is to evaluate the effectiveness and safety of this combined strategy. Target volunteers must not have received any treatments for their advanced or metastatic NSCLC. Participation includes receiving either the combined treatment or pembrolizumab alone. Regular health checks will monitor if any changes or adverse events occur during the trial.

    • Dato-DXd
    • Pembrolizumab
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    • Pertuzumab
    • Tucatinib
    • Trastuzumab
  • Examining new drug combo vs. standard treatment with pembrolizumab for advanced lung cancer

    This trial is examining if a combination of two medications, Dato-DXd and pembrolizumab, could be superior to using pembrolizumab alone in treating a type of lung cancer known as metastatic non-small cell lung cancer (NSCLC). Participants will include those who have advanced or spread NSCLC and haven’t had systemic treatment for it. The team will be comparing whether the combination treatment can help patients live longer or keep the cancer from growing for a longer period. One group of participants will get pembrolizumab on its own, while another will get both Dato-DXd and pembrolizumab. An important part of the study will assess how the treatment affects the patient’s symptoms and quality of life.

    • Datopotamab deruxtecan
    • Pembrolizumab

See more clinical trials in other cities in Poland:

.